EVALUATION OF EARLY TREATMENT OUTCOMES OF PERITONSILLAR ABSCESS WITHIN THE FIRST 72 HOURS AT THE NATIONAL ENT HOSPITAL
Main Article Content
Abstract
This study was conducted on 136 patients with peritonsillar abscess treated at the National Otorhinolaryngology Hospital from July 1, 2024, to June 30, 2025, with the objective of evaluating treatment outcomes within the first 72 hours. The mean age of participants was 45.16 ± 14.80 years, the male/female ratio is 2.68/1. The mean duration of symptoms before admission was 5.2 ± 3.2 days; 86% of patients had received antibiotics prior to hospitalization. Potential triggering and contributing factors included recurrent tonsillitis (27.9%) and diabetes mellitus (11%). The most common antibiotic regimen involved a combination of a broad-spectrum antibiotic with an agent active against anaerobes (76.4%), most frequently quinolone plus metronidazole (60.3%); triple-antibiotic combinations were used in 22.1%, and monotherapy in only 1.5% of cases. Treatment outcomes within 72 hours were generally favorable, with good response in 53.7%, moderate response in 34.6%, and poor response in only 11.8%. No statistically significant difference in outcomes was observed between different antibiotic regimens.
Article Details
Keywords
Peritonsillar abscess, bacteria, antibiotics, treatment outcome
References
2. Klug TE, et al. The bacteriology of peritonsillar abscess. J Clin Microbiol. 2009;47(8):2329-2333.
3. Johnson RF, Stewart MG. The contemporary approach to diagnosis and management of peritonsillar abscess. Curr Opin Otolaryngol Head Neck Surg. 2005;13(3):157-160.
4. Trương Kim Tri. Nghiên cứu vi khuẩn gây áp xe quanh amiđan tại TP.HCM. Tạp chí Y học Việt Nam. 2003.
5. Sowerby LJ, Hussain Z. Microbiology and antibiotic resistance of peritonsillar abscesses. J Otolaryngol Head Neck Surg. 2013;42:43.
6. Tsai YT, et al. Increasing prevalence of anaerobes in peritonsillar abscess: A 24-year retrospective study. J Microbiol Immunol Infect. 2018;51(1):74–79.
7. Klug TE, et al. Changes in peritonsillar abscess microbiology after COVID-19 lockdown. Clin Otolaryngol. 2021;46(6):1141-1145.
8. Bigdeli R, et al. Review of management of peritonsillar abscess in Australia. ANZ J Surg. 2022;92(1-2):79–84.
9. Takano S, et al. Comparison of two-drug regimens in treatment of peritonsillar abscess. J Infect Chemother. 2019;25(4):296-300.
10. Hà N. T. & San N. N. Đặc điểm lâm sàng và vi khuẩn học áp xe quanh amiđan tại Bệnh viện Tai Mũi Họng Trung ương từ 01/09/2023 đến 31/03/2024. TCNCYH 182, 86–96 (2024).